{"shortAnswer":"GHRP-2 has no approved use in the US, and no pharmacy may lawfully make it. Its shots and nasal sprays are on FDA's Category 2 list. The evidence grade is limited-human: small studies show it raises growth hormone and hunger, but none tested it for muscle or recovery.","url":"https://peptideindex.ai/compound/ghrp-2","status":"no-approved-use","statusCheckedAt":"2026-10-26T13:32:22.332Z","statusStale":false,"regulatoryAsOf":"2026-10-25","verified":"2026-10-26T13:32:22.378Z","primarySourceUrl":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/triad-rx-inc-569659-02052019","clinicallyReviewed":false,"notice":"Information, not medical advice.","id":"4ff116c6-ed8a-4096-90eb-cb0959e4c75e","object":"compound","slug":"ghrp-2","name":"GHRP-2","attrs":{"name":"GHRP-2","class":"growth-hormone-axis","access":[{"type":"lawful-compounding","detail":"For forms other than shots and nasal sprays, GHRP-2 is in Category 1 of FDA's outsourcing list. An outsourcing facility may make it while FDA decides, if it meets the policy's conditions. No pharmacy may make it, and no shot or nasal spray has a legal route.","source_url":"https://www.fda.gov/media/94164/download"}],"trials":[],"aliases":["pralmorelin","growth hormone releasing peptide-2","GHRP 2","KP-102","GPA 748"],"summary":"A lab-made peptide that copies ghrelin and makes the body release growth hormone. US drug testing of it appears to have stopped.","citations":[{"n":1,"url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","tier":"primary","type":"regulatory","title":"FDA: bulk drug substances that may present significant safety risks, with GHRP-2 shots and nasal sprays added in 2023"},{"n":2,"url":"https://www.fda.gov/media/94155/download","tier":"primary","type":"regulatory","title":"FDA: bulk drug substances nominated under section 503A, list updated 14 May 2026"},{"n":3,"url":"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act","tier":"primary","type":"regulatory","title":"FDA: bulk drug substances used in compounding under section 503A"},{"n":4,"url":"https://www.fda.gov/media/94164/download","tier":"primary","type":"regulatory","title":"FDA: bulk drug substances nominated under section 503B, list updated 21 March 2025"},{"n":5,"url":"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act","tier":"primary","type":"regulatory","title":"FDA: bulk drug substances used in compounding under section 503B"},{"n":6,"url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/triad-rx-inc-569659-02052019","tier":"primary","type":"regulatory","title":"FDA warning letter to a compounding pharmacy that made drugs from GHRP-2, 5 February 2019"},{"n":7,"url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailor-made-compounding-llc-594743-04012020","tier":"primary","type":"regulatory","title":"FDA warning letter to a compounding pharmacy that made drugs from GHRP-2 and other peptides, 1 April 2020"},{"n":8,"url":"https://djholtlaw.com/navigating-the-2026-peptide-regulatory-landscape-federal-compliance-state-enforcement-and-the-legal-liabilities-of-healthcare-providers/","tier":"legal-analysis","type":"legal-analysis","title":"Holt Law: the 2026 federal rules on peptides and the risks for prescribers"},{"n":9,"url":"https://pubmed.ncbi.nlm.nih.gov/12030918/","tier":"peer-reviewed","type":"human-trial","title":"GHRP-2 alone and with two other hormones in men with long critical illness, 2002"},{"n":10,"url":"https://pubmed.ncbi.nlm.nih.gov/14513874/","tier":"peer-reviewed","type":"human-trial","title":"GHRP-2 by mouth, appetite and weight in children short of growth hormone, 2003"},{"n":11,"url":"https://pubmed.ncbi.nlm.nih.gov/16861611/","tier":"peer-reviewed","type":"human-trial","title":"GHRP-2 and how much lean and obese people ate, 2006"},{"n":12,"url":"https://pubmed.ncbi.nlm.nih.gov/10337858/","tier":"peer-reviewed","type":"human-trial","title":"Growth hormone release after GHRP-2 before and during prednisone, 1999"},{"n":13,"url":"https://pubmed.ncbi.nlm.nih.gov/19577604/","tier":"peer-reviewed","type":"animal","title":"GHRP-2 and muscle breakdown in rats with burns, 2009"},{"n":14,"url":"https://pubmed.ncbi.nlm.nih.gov/16030067/","tier":"peer-reviewed","type":"animal","title":"GHRP-2 and muscle-wasting genes in rats with arthritis, 2005"},{"n":15,"url":"https://pubmed.ncbi.nlm.nih.gov/20805679/","tier":"peer-reviewed","type":"animal","title":"GHRP-2 and lung injury in rats, 2010"},{"n":16,"url":"https://pubmed.ncbi.nlm.nih.gov/18191156/","tier":"peer-reviewed","type":"in-vitro","title":"GHRP-2 in rat muscle and in lab-grown muscle cells, 2008"},{"n":17,"url":"https://pubmed.ncbi.nlm.nih.gov/42395176/","tier":"peer-reviewed","type":"reference","title":"Review: peptides sold to raise growth hormone, including GHRP-2, and their reported harms, 2026"},{"n":18,"url":"https://pubmed.ncbi.nlm.nih.gov/15230633/","tier":"peer-reviewed","type":"reference","title":"Drug profile of pralmorelin, the drug name for GHRP-2, 2004"},{"n":19,"url":"https://www.pharmacytimes.com/view/the-peptide-reclassification-everyone-s-talking-about-a-pharmacist-s-take-on-what-rfk-jr-s-announcement-actually-means","tier":"established-news","type":"reference","title":"Pharmacy Times: a pharmacist on the February 2026 peptide announcement"}],"known_risks":["FDA warns that GHRP-2 shots and nasal sprays made by a compounder may set off the immune system. The peptide can clump and carry impurities [^1].","FDA knows of serious harms in people given GHRP-2: higher insulin needs to control blood sugar, infection, pancreatitis (a swollen pancreas) and deaths of very ill study subjects. FDA says it has not shown that GHRP-2 caused them [^1].","GHRP-2 raises hunger. In a small study, adults given it ate up to a third more food at a meal [^11].","A 2026 review lists harms in people who used peptides like GHRP-2 on their own. These include hormone and blood sugar changes, fluid build-up, muscle and joint pain, and skin reactions where the needle went in [^17]."],"short_answer":"GHRP-2 has no approved use in the US, and no pharmacy may lawfully make it. Its shots and nasal sprays are on FDA's Category 2 list. The evidence grade is limited-human: small studies show it raises growth hormone and hunger, but none tested it for muscle or recovery.","evidence_grade":"limited-human","open_questions":["None of the human studies we cite tested GHRP-2 for muscle or recovery in healthy people [^9] [^10] [^11] [^12].","A rise in growth hormone on a blood test is a lab marker. Nobody knows if that rise leads to the gains GHRP-2 is sold for [^12] [^17].","Nobody knows what years of use do. The longest study in our sources lasted one year, in ten children [^10].","The muscle results come from rats and lab-grown cells. Nobody knows if they hold in people [^13] [^14] [^16].","FDA has not found whether GHRP-2 caused the serious harms reported in people who received it [^1]."],"section_routes":"No approved drug in the US contains GHRP-2, and no pharmacy may lawfully make it [^6] [^3]. No shot or nasal spray of GHRP-2 has a legal route [^1] [^4].\n\nOne narrow route exists. An outsourcing facility may make GHRP-2 in forms other than shots and nasal sprays, if it meets the conditions of FDA's policy [^4] [^5]. That does not make GHRP-2 approved, and FDA may take a substance off Category 1, for example over safety [^5].\n\nAny open trial would appear in the trials block below, with the date the official registry was last checked.","status_by_route":[{"route":"Shots and nasal sprays","status":"category-2","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"route":"Other forms, such as by mouth","status":"no-approved-use","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/triad-rx-inc-569659-02052019"}],"regulatory_as_of":"2026-10-25","section_channels":"Two ways of getting GHRP-2 show up in the records [^6] [^17]. The first is pharmacies that make it although the law does not allow it. FDA has sent warning letters to pharmacies that made drugs from GHRP-2 [^6] [^7]. One pharmacy told FDA it had dropped GHRP-2 from its products [^7].\n\nThe second is online sellers that market it as a research compound. A 2026 review says what these products hold, and how strong they are, is uncertain [^17]. FDA says a product meant to affect the body is a drug, and a new drug needs FDA approval [^6]. No GHRP-2 product has it [^6].\n\nFDA warns that compounded GHRP-2 shots may carry impurities that set off the immune system [^1]. FDA also knows of serious harms in people given GHRP-2, though it has not shown that GHRP-2 caused them [^1].","section_evidence":"The evidence grade is limited-human: small studies in people show GHRP-2 raises growth hormone and hunger, but none tested the uses it is sold for [^10] [^11] [^12] [^17].\n\nIn eight people, GHRP-2 raised growth hormone far more than arginine, a standard test, both before and during treatment with prednisone, a steroid [^12]. In 19 healthy adults, lean and obese, GHRP-2 given under the skin raised growth hormone and made them eat more at lunch [^11]. In ten children short of growth hormone, GHRP-2 by mouth for a year raised appetite in seven of them early on [^10]. Their weight for their height did not change by a meaningful amount [^10]. In 33 men with long critical illness, GHRP-2 alone did not bring the helpful effects on body breakdown that a mix of three hormones brought [^9].\n\nIn rats, GHRP-2 slowed muscle breakdown after burns [^13]. In rats with arthritis, it blocked genes tied to muscle wasting [^14]. In rats with lung injury, it reduced lung swelling [^15]. In rat muscle and in muscle cells grown in a lab, it lowered two genes tied to muscle wasting [^16]. These are animal and lab results, not results in people.\n\nA rise in growth hormone on a test is a lab marker. It does not show more muscle or faster recovery [^17]. A 2026 review says the benefits for sports and body shape are uncertain [^17].","regulatory_status":"no-approved-use","section_what_it_is":"GHRP-2 is a lab-made chain of six amino acids [^13]. Amino acids are the building blocks of proteins. It copies ghrelin, a hormone that tells the body to release growth hormone [^18]. Its drug name is pralmorelin [^18]. One of its amino acids is not found in nature, which makes a product harder to check [^1].\n\nResearchers at a US university made GHRP-2 and related peptides [^18]. A drug company tested it in the US for growth hormone shortage, but that work seems to have stopped [^18]. A 2004 drug profile says it was awaiting approval in Japan as a test of the pituitary gland [^18]. That is a gland at the base of the brain that makes growth hormone. Today GHRP-2 is sold online as a research compound for body shape and sports [^17].","section_is_it_legal":"GHRP-2 has no approved use in the US: FDA says it is in no approved drug and does not meet the rules for pharmacy compounding [^6] [^2]. That means no pharmacy may lawfully make it. Work on it as a test in Japan does not change its US status [^18]. Its shots and nasal sprays are also on Category 2, FDA's list of substances that may present significant safety risks [^1]. Checked 25 October 2026.\n\nFDA keeps lists for two kinds of compounders. A pharmacy is covered by section 503A of the law. An outsourcing facility is covered by section 503B [^3] [^5]. On FDA's pharmacy list of 14 May 2026, GHRP-2 is in Category 3 [^2]. That category holds substances nominated without enough support for FDA to review them [^2]. FDA says it may act against a pharmacy that compounds one [^3].\n\nOn FDA's outsourcing list of 21 March 2025, GHRP-2 shots and nasal sprays are in Category 2 [^4]. FDA added them on 29 September 2023 [^1]. Other forms are in Category 1 on that list [^4]. FDA says it does not plan to act against an outsourcing facility that makes a Category 1 substance under the policy's conditions [^5]. That is a choice not to act, not approval [^5].\n\nGHRP-2 was studied as a test for growth hormone shortage [^18]. It is sold to build muscle and change body shape [^17]. A law firm and a pharmacy magazine expected it to stay restricted after a February 2026 federal announcement on peptides [^8] [^19]. Neither changes FDA's own lists, which this page follows [^2] [^4].","unofficial_channels":[{"type":"compounding-outside-the-rules","what_it_is":"Made by a pharmacy from bulk GHRP-2 powder, although it does not meet the rules for pharmacy compounding.","enforcement":[{"date":"2019-02-05","text":"FDA warning letter to an Alabama compounding pharmacy that made drugs from GHRP-2.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/triad-rx-inc-569659-02052019"},{"date":"2020-04-01","text":"FDA warning letter to a Kentucky compounding pharmacy that made drugs from GHRP-2 and other peptides.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailor-made-compounding-llc-594743-04012020"}],"legal_position":{"text":"FDA says drugs made from GHRP-2 do not qualify for the compounding exemptions. It is in no approved drug and is not on the federal list.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/triad-rx-inc-569659-02052019"},"documented_risks":[{"text":"FDA warns that compounded GHRP-2 shots and nasal sprays may set off the immune system, because the peptide can clump and carry impurities.","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"text":"FDA knows of serious harms in people given GHRP-2, including infection and a swollen pancreas, though FDA has not shown that GHRP-2 caused them.","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"}]},{"type":"research-use-seller","what_it_is":"Sold online as a research compound, often to people seeking muscle or a change in body shape.","legal_position":{"text":"FDA says a product meant to affect the body is a drug, and a new drug needs FDA approval. No GHRP-2 product is approved.","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/triad-rx-inc-569659-02052019"},"documented_risks":[{"text":"A 2026 review says what these products hold, and how strong they are, is uncertain.","source_url":"https://pubmed.ncbi.nlm.nih.gov/42395176/"},{"text":"The same review lists hormone and blood sugar changes, fluid build-up and needle-site reactions in people using these peptides.","source_url":"https://pubmed.ncbi.nlm.nih.gov/42395176/"}]}]},"provenance":{"name":{"fact_id":"1d70c433-f9da-4742-9aa3-2d1312c7ae2a","source_url":"https://pubmed.ncbi.nlm.nih.gov/15230633/","source_type":"peer-reviewed","captured_at":"2026-10-26T06:06:57.088Z","checked_at":"2026-10-26T13:32:22.369Z","confidence":1,"stale":false},"class":{"fact_id":"1537f50d-eb5e-43ba-bbf0-e1ee2e0ae518","source_url":"https://pubmed.ncbi.nlm.nih.gov/15230633/","source_type":"peer-reviewed","captured_at":"2026-10-26T06:06:57.088Z","checked_at":"2026-10-26T13:32:22.372Z","confidence":1,"stale":false},"access":{"fact_id":"b9933639-732e-4b44-8cda-9404cb4aa2a8","source_url":"https://www.fda.gov/media/94164/download","source_type":"primary","captured_at":"2026-10-26T06:06:48.104Z","checked_at":"2026-10-26T13:32:22.313Z","confidence":1,"stale":false},"trials":{"fact_id":"09163565-ae88-4817-8577-989bc9cfa1e4","source_url":"https://clinicaltrials.gov/api/v2/studies?query.intr=GHRP-2+OR+pralmorelin&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING&pageSize=50&sort=StartDate%3Adesc&countTotal=true&fields=NCTId%2CBriefTitle%2COverallStatus%2CPhase%2CLeadSponsorName%2CStartDate%2CLocationCountry%2CLocationState","source_type":"primary","captured_at":"2026-10-26T13:32:35.100Z","checked_at":"2026-10-26T13:32:35.100Z","confidence":1,"stale":false},"aliases":{"fact_id":"72b36861-3765-41da-ae36-5b0743afe7fa","source_url":"https://pubmed.ncbi.nlm.nih.gov/15230633/","source_type":"peer-reviewed","captured_at":"2026-10-26T06:06:57.088Z","checked_at":"2026-10-26T13:32:22.371Z","confidence":1,"stale":false},"summary":{"fact_id":"8386b146-b332-45ca-a7c0-e465646a77c9","source_url":"https://pubmed.ncbi.nlm.nih.gov/15230633/","source_type":"peer-reviewed","captured_at":"2026-10-26T06:06:57.088Z","checked_at":"2026-10-26T13:32:22.350Z","confidence":1,"stale":false},"citations":{"fact_id":"16138f53-6aba-4b54-8de0-aecfd0858bca","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","source_type":"primary","captured_at":"2026-10-24T03:43:00.387Z","checked_at":"2026-10-26T13:32:22.378Z","confidence":1,"stale":false},"known_risks":{"fact_id":"ab1e50f9-aea9-4b2d-8237-bfa967ffe0e5","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","source_type":"primary","captured_at":"2026-10-24T03:43:00.387Z","checked_at":"2026-10-26T13:32:22.365Z","confidence":1,"stale":false},"short_answer":{"fact_id":"98055dfc-c325-40fd-a2ed-b4e309956d9c","source_url":"https://peptideindex.ai/methodology#short-answer","source_type":"reference","captured_at":"2026-10-25T00:14:44.418Z","checked_at":"2026-10-26T13:32:22.359Z","confidence":1,"stale":false,"label":"our assessment"},"evidence_grade":{"fact_id":"d895ef21-498c-41df-b5aa-20f6c475288d","source_url":"https://peptideindex.ai/methodology#evidence-grade","source_type":"reference","captured_at":"2026-10-25T00:14:45.193Z","checked_at":"2026-10-26T13:32:22.363Z","confidence":1,"stale":false,"label":"our assessment"},"open_questions":{"fact_id":"b0ac6685-965a-4384-927d-d519ba3f7bcd","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","source_type":"primary","captured_at":"2026-10-24T03:43:00.387Z","checked_at":"2026-10-26T13:32:22.328Z","confidence":1,"stale":false},"section_routes":{"fact_id":"f37e5d63-f5e3-4c4b-b264-c69aef3d7a8c","source_url":"https://www.fda.gov/media/94164/download","source_type":"primary","captured_at":"2026-10-26T06:06:48.104Z","checked_at":"2026-10-26T13:32:22.375Z","confidence":1,"stale":false},"status_by_route":{"fact_id":"b8b0b89f-8091-4282-a4e8-db64e37d1dd5","source_url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","source_type":"primary","captured_at":"2026-10-24T03:43:00.387Z","checked_at":"2026-10-26T13:32:22.347Z","confidence":1,"stale":false},"regulatory_as_of":{"fact_id":"5abe41c3-e760-4a23-b775-405efb816a09","source_url":"https://www.fda.gov/media/94155/download","source_type":"primary","captured_at":"2026-10-26T06:06:47.298Z","checked_at":"2026-10-26T13:32:22.361Z","confidence":1,"stale":false},"section_channels":{"fact_id":"5102e42f-ca24-49e9-a6d7-686b5cdbe257","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/triad-rx-inc-569659-02052019","source_type":"primary","captured_at":"2026-10-26T06:05:14.747Z","checked_at":"2026-10-26T13:32:22.336Z","confidence":1,"stale":false},"section_evidence":{"fact_id":"0ea5fe06-a6a1-4c75-b874-64429d2718e1","source_url":"https://pubmed.ncbi.nlm.nih.gov/42395176/","source_type":"peer-reviewed","captured_at":"2026-10-26T06:06:56.272Z","checked_at":"2026-10-26T13:32:22.374Z","confidence":1,"stale":false},"regulatory_status":{"fact_id":"a8e08741-c2e1-4e87-afc4-ab682d7b90e6","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/triad-rx-inc-569659-02052019","source_type":"primary","captured_at":"2026-10-26T06:05:14.747Z","checked_at":"2026-10-26T13:32:22.332Z","confidence":1,"stale":false},"section_what_it_is":{"fact_id":"5441b4d3-da14-4397-ad37-b2bae22266e4","source_url":"https://pubmed.ncbi.nlm.nih.gov/15230633/","source_type":"peer-reviewed","captured_at":"2026-10-26T06:06:57.088Z","checked_at":"2026-10-26T13:32:22.367Z","confidence":1,"stale":false},"section_is_it_legal":{"fact_id":"91235816-140e-435d-87ab-d32b5dcbd22b","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/triad-rx-inc-569659-02052019","source_type":"primary","captured_at":"2026-10-26T06:05:14.747Z","checked_at":"2026-10-26T13:32:22.343Z","confidence":1,"stale":false},"unofficial_channels":{"fact_id":"490f89d9-9d20-44aa-991e-ea7dced6ac35","source_url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/triad-rx-inc-569659-02052019","source_type":"primary","captured_at":"2026-10-26T06:05:14.747Z","checked_at":"2026-10-26T13:32:22.355Z","confidence":1,"stale":false}},"citationsBySection":{"known_risks":[{"n":1,"title":"FDA: bulk drug substances that may present significant safety risks, with GHRP-2 shots and nasal sprays added in 2023","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"n":11,"title":"GHRP-2 and how much lean and obese people ate, 2006","url":"https://pubmed.ncbi.nlm.nih.gov/16861611/"},{"n":17,"title":"Review: peptides sold to raise growth hormone, including GHRP-2, and their reported harms, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42395176/"}],"open_questions":[{"n":9,"title":"GHRP-2 alone and with two other hormones in men with long critical illness, 2002","url":"https://pubmed.ncbi.nlm.nih.gov/12030918/"},{"n":10,"title":"GHRP-2 by mouth, appetite and weight in children short of growth hormone, 2003","url":"https://pubmed.ncbi.nlm.nih.gov/14513874/"},{"n":11,"title":"GHRP-2 and how much lean and obese people ate, 2006","url":"https://pubmed.ncbi.nlm.nih.gov/16861611/"},{"n":12,"title":"Growth hormone release after GHRP-2 before and during prednisone, 1999","url":"https://pubmed.ncbi.nlm.nih.gov/10337858/"},{"n":17,"title":"Review: peptides sold to raise growth hormone, including GHRP-2, and their reported harms, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42395176/"},{"n":13,"title":"GHRP-2 and muscle breakdown in rats with burns, 2009","url":"https://pubmed.ncbi.nlm.nih.gov/19577604/"},{"n":14,"title":"GHRP-2 and muscle-wasting genes in rats with arthritis, 2005","url":"https://pubmed.ncbi.nlm.nih.gov/16030067/"},{"n":16,"title":"GHRP-2 in rat muscle and in lab-grown muscle cells, 2008","url":"https://pubmed.ncbi.nlm.nih.gov/18191156/"},{"n":1,"title":"FDA: bulk drug substances that may present significant safety risks, with GHRP-2 shots and nasal sprays added in 2023","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"}],"section_routes":[{"n":6,"title":"FDA warning letter to a compounding pharmacy that made drugs from GHRP-2, 5 February 2019","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/triad-rx-inc-569659-02052019"},{"n":3,"title":"FDA: bulk drug substances used in compounding under section 503A","url":"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act"},{"n":1,"title":"FDA: bulk drug substances that may present significant safety risks, with GHRP-2 shots and nasal sprays added in 2023","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"n":4,"title":"FDA: bulk drug substances nominated under section 503B, list updated 21 March 2025","url":"https://www.fda.gov/media/94164/download"},{"n":5,"title":"FDA: bulk drug substances used in compounding under section 503B","url":"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act"}],"section_channels":[{"n":6,"title":"FDA warning letter to a compounding pharmacy that made drugs from GHRP-2, 5 February 2019","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/triad-rx-inc-569659-02052019"},{"n":17,"title":"Review: peptides sold to raise growth hormone, including GHRP-2, and their reported harms, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42395176/"},{"n":7,"title":"FDA warning letter to a compounding pharmacy that made drugs from GHRP-2 and other peptides, 1 April 2020","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tailor-made-compounding-llc-594743-04012020"},{"n":1,"title":"FDA: bulk drug substances that may present significant safety risks, with GHRP-2 shots and nasal sprays added in 2023","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"}],"section_evidence":[{"n":10,"title":"GHRP-2 by mouth, appetite and weight in children short of growth hormone, 2003","url":"https://pubmed.ncbi.nlm.nih.gov/14513874/"},{"n":11,"title":"GHRP-2 and how much lean and obese people ate, 2006","url":"https://pubmed.ncbi.nlm.nih.gov/16861611/"},{"n":12,"title":"Growth hormone release after GHRP-2 before and during prednisone, 1999","url":"https://pubmed.ncbi.nlm.nih.gov/10337858/"},{"n":17,"title":"Review: peptides sold to raise growth hormone, including GHRP-2, and their reported harms, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42395176/"},{"n":9,"title":"GHRP-2 alone and with two other hormones in men with long critical illness, 2002","url":"https://pubmed.ncbi.nlm.nih.gov/12030918/"},{"n":13,"title":"GHRP-2 and muscle breakdown in rats with burns, 2009","url":"https://pubmed.ncbi.nlm.nih.gov/19577604/"},{"n":14,"title":"GHRP-2 and muscle-wasting genes in rats with arthritis, 2005","url":"https://pubmed.ncbi.nlm.nih.gov/16030067/"},{"n":15,"title":"GHRP-2 and lung injury in rats, 2010","url":"https://pubmed.ncbi.nlm.nih.gov/20805679/"},{"n":16,"title":"GHRP-2 in rat muscle and in lab-grown muscle cells, 2008","url":"https://pubmed.ncbi.nlm.nih.gov/18191156/"}],"section_what_it_is":[{"n":13,"title":"GHRP-2 and muscle breakdown in rats with burns, 2009","url":"https://pubmed.ncbi.nlm.nih.gov/19577604/"},{"n":18,"title":"Drug profile of pralmorelin, the drug name for GHRP-2, 2004","url":"https://pubmed.ncbi.nlm.nih.gov/15230633/"},{"n":1,"title":"FDA: bulk drug substances that may present significant safety risks, with GHRP-2 shots and nasal sprays added in 2023","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"n":17,"title":"Review: peptides sold to raise growth hormone, including GHRP-2, and their reported harms, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42395176/"}],"section_is_it_legal":[{"n":6,"title":"FDA warning letter to a compounding pharmacy that made drugs from GHRP-2, 5 February 2019","url":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/triad-rx-inc-569659-02052019"},{"n":2,"title":"FDA: bulk drug substances nominated under section 503A, list updated 14 May 2026","url":"https://www.fda.gov/media/94155/download"},{"n":18,"title":"Drug profile of pralmorelin, the drug name for GHRP-2, 2004","url":"https://pubmed.ncbi.nlm.nih.gov/15230633/"},{"n":1,"title":"FDA: bulk drug substances that may present significant safety risks, with GHRP-2 shots and nasal sprays added in 2023","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"n":3,"title":"FDA: bulk drug substances used in compounding under section 503A","url":"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act"},{"n":5,"title":"FDA: bulk drug substances used in compounding under section 503B","url":"https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act"},{"n":4,"title":"FDA: bulk drug substances nominated under section 503B, list updated 21 March 2025","url":"https://www.fda.gov/media/94164/download"},{"n":17,"title":"Review: peptides sold to raise growth hormone, including GHRP-2, and their reported harms, 2026","url":"https://pubmed.ncbi.nlm.nih.gov/42395176/"},{"n":8,"title":"Holt Law: the 2026 federal rules on peptides and the risks for prescribers","url":"https://djholtlaw.com/navigating-the-2026-peptide-regulatory-landscape-federal-compliance-state-enforcement-and-the-legal-liabilities-of-healthcare-providers/"},{"n":19,"title":"Pharmacy Times: a pharmacist on the February 2026 peptide announcement","url":"https://www.pharmacytimes.com/view/the-peptide-reclassification-everyone-s-talking-about-a-pharmacist-s-take-on-what-rfk-jr-s-announcement-actually-means"}]},"channelsOpener":"This section describes what happens and is not a recommendation.","sources":["https://clinicaltrials.gov/api/v2/studies?query.intr=GHRP-2+OR+pralmorelin&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING&pageSize=50&sort=StartDate%3Adesc&countTotal=true&fields=NCTId%2CBriefTitle%2COverallStatus%2CPhase%2CLeadSponsorName%2CStartDate%2CLocationCountry%2CLocationState","https://peptideindex.ai/methodology#evidence-grade","https://peptideindex.ai/methodology#short-answer","https://pubmed.ncbi.nlm.nih.gov/15230633/","https://pubmed.ncbi.nlm.nih.gov/42395176/","https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/triad-rx-inc-569659-02052019","https://www.fda.gov/media/94155/download","https://www.fda.gov/media/94164/download"],"verified_at":"2026-10-26T13:32:22.378Z","published_at":"2026-10-26T13:49:24.221Z","parent":null,"children":[],"snapshots":{"trials":{"snapshot_at":"2026-10-26T13:32:35.100Z","stale":false,"notice":"A listing is not a recommendation. Trials have strict eligibility rules. Talk to your doctor and read the official record."}}}